Cat-1 inhibitors, pharmaceutical compositions and methods of use

Details Cat-1 inhibitors, pharmaceutical compositions and methods of use Cat-1 inhibitors, pharmaceutical compositions and methods of use

1992-03-13

1994-09-06

Raymond, Richard L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514277, 514306, 514307, 514336, 514337, 514461, 514471, 514472, 514561, 514562, 514563, 514570, 514571, 546143, 546147, 546167, 546171, 546172, 546174, 546284, 546300, 546301, 549 64, 549 65, 549 66, 549 68, 549 69, 549 72, 549 77, 549 79, 562435, 562443, 562444, 562449, 562450, 562452, 562463, 562460, 562490, 562492, 562495, 562496, A61K 3119, A61K 3138, C07C 6540, C07D33332

Patent

active

053448430

ABSTRACT:
The invention relates to compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.2 ' X, Y, Z, A, B, Q and n are as described herein. Their pharmaceutically acceptable salts, and when appropriate, enantiomers, racemates, diastereomers or mixtures thereof or geometric isomer or mixtures thereof, and pharmaceutically acceptable salts thereof. The compounds of formula I inhibit enzyme carnitine acyltransferase 1 (CAT-1) and are therefore useful in the prevention of injury to ischemic tissue, and can limit infarct size, improve cardiac function and prevent arrhythmias during and following a myocardial infarction.

REFERENCES:
patent: 3969119 (1976-07-01), Muzyczko et al.
patent: 4018921 (1977-04-01), Gleason
patent: 4304930 (1981-12-01), Palosi et al.
patent: 4393008 (1983-07-01), Palosi et al.
patent: 4675439 (1987-06-01), Mita et al.
patent: 4814339 (1989-03-01), Rotondo
patent: 5004817 (1991-04-01), Bastioli et al.
patent: 5070087 (1991-12-01), Teng et al.
Elkaschief et al., Chemical Abstracts, vol. 83 (1975) 429944e.
Chemical Abstracts, vol. 88 (1977) 104914j.
Bouzard et al., Chemical Abstracts, vol. 88 (1977) 105365t.
Cross et al., Chemical Abstracts, vol. 95 (1981) 169183j.
Hilball et al., Chemical Abstracts, vol. 98 (1983) 198224r.
Domagala, Tetrahedron Letters, vol. 21 (1980) pp. 4997-5000.
W. Foye, "Principles of Medicinal Chemistry" 2nd ed., p. 80, Lea & Febiger, Philadelphia (1981).
Patent Abstract of Japan, vol. 12, No. 333 (C-526)(3180) for JP-A-63 096 152 (Canon Inc.) Apr. 27, 1988).
J. Mol. Cell Cardiol., 19 509-520 (1987).
Am. J. Cardiol. 48: 702-710.
Life Science vol. 27, pp. 963-970.
Basic Res. Cardiol. 81: 258-266 (1986).
Biochem. Biophys. Res. Commun: 100,, 291-296 (1981).
Proceedings of the B.P.S. Apr. 4th-6th 1979, 443P-444P.
Life Sciences, vol. 29, pp. 1847-1853 (1980).
Naunyn-Schmiedeberg's Arch. Pharmacol. (1984) 327: 70-74.
J. Med. Cell Cardiol 17, 619-625 (1985).
Research Commun. in Chem. Path. and Pharmacology vol. 26, No. 3, Dec. 1979.
Basic Res. Cardiol. 78, 19-27 (1983).
J. Moll Cell. Cardiol 20, 277-282 (1988).
G. M. Salituro et al., J. Am. Chem. Soc., Total Synthesis of (-) --Nocardicins A-G; A Biogenetic Approach 112(2) pp. 760-770 (1990).
W. D. Sprung et al., Pharmazie, Zur Synthese p-substitiuester DL-2-Phenylglycinocyylester, 44 (48), pp. 540-542 (1989).
T. W. Greene, Protective Groups in Organic Synthesis, pp. 249 and 330, John Wiley & Sons, New York (1981).
I. T. Barnish et al., J. Med. Chem., Promotion of Carbohydrate Oxidation in the Heart by Some Phenylglyoxylic Acids, 24, pp. 399-404 (1981).
E. M. Gordon et al., J. Org. Chem., 44, No. 8, pp. 1218-1221 (1979).

Affiliated with

Also associated with

Rating

Cat-1 inhibitors, pharmaceutical compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cat-1 inhibitors, pharmaceutical compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cat-1 inhibitors, pharmaceutical compositions and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1329712